Abstract
In the United States, SARS-CoV-2 genomic surveillance initially relied almost entirely on residual diagnostic specimens from nucleic acid amplification-based tests (NAATs). The use of NAATs waned after the end of the COVID-19 Public Health Emergency. We partnered with local- and state-level public health agencies and the Dane County Public Library System to continue genomic surveillance by obtaining SARS-CoV-2 genome sequences from freely available community rapid antigen tests (RATs). From August 15, 2023 to February 29, 2024 we received 227 tests, from which we generated 127 sequences with >10x depth of coverage for ≥90% of the genome. In a subset of tests, lower Ct values correlated with sequence success. Our results demonstrate that collecting and sequencing from RATs in partnership with community sites is a practical approach for sustaining SARS-CoV-2 genomic surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Wisconsin Department of Health Services [435100-A24-ELCProjE] and the CDC [75D30122C15355].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Wisconsin IRB determined that this human research was exempt because partici-pants were anonymous and self-identified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We received feedback from our intended publication journal, the CDC's Emerging Infectious Diseases, and this updated manuscript is the result of addressing this feedback. We have substantially shortened the text (removed over 1,300 words), which was required by the journal. We have removed ideas not central to the manuscript. The introduction, results, and discussion were most impacted by this reduction. Figure 1 was updated to remove the inset. Figure 4 was updated to include total count of samples per bar. The appendix has been updated with more supplemental material to clarify methods and sequencing results. There is now methods in the appendix describing our RT-qPCR methods more in depth. Appendix Figure 1 was added to show our recruitment file. Appendix Table 1 was added to show the sequencing metrics for each sample included in our study. Updated supplemental file to not include Spanish version of our flyer.
Data Availability
The sequencing data generated in this study are available in the Sequence Read Archive (SRA) under the BioProject PRJNA1096364. The accession numbers to the sequences used in these analyses are available in Appendix Table 2 of this manuscript.
https://github.com/dholab/Library-Rapid-Antigen-Test-Manuscript
